102 related articles for article (PubMed ID: 3204307)
1. [Clinical study of combination chemotherapy with CDDP, ADM and CPM for ovarian cancer].
Kobayashi H; Maeda M; Hayata T; Kawashima Y
Nihon Gan Chiryo Gakkai Shi; 1988 Apr; 23(4):829-36. PubMed ID: 3204307
[No Abstract] [Full Text] [Related]
2. [Chemotherapy of ovarian tumors using cis-platin].
Laurová L; Kobilková J; Novotná J; Motlík K; Fricová M; Hornický J
Cesk Gynekol; 1987 Feb; 52(1):41-4. PubMed ID: 3568161
[No Abstract] [Full Text] [Related]
3. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
[TBL] [Abstract][Full Text] [Related]
4. [Combined modality for recurrent and disseminated ovarian cancer--CAPF combination chemotherapy and second-look operation].
Inagaki J; Ogawa M; Horikoshi N; Ezaki K; Inoue K; Aiba K; Komyo M; Miyamoto H; Ikeda K; Kubo H
Gan No Rinsho; 1983 Aug; 29(10):1291-5. PubMed ID: 6685195
[TBL] [Abstract][Full Text] [Related]
5. [Increase in CDDP therapeutic index by lower concentration and longer infusion time--home chemotherapy for ovarian cancer].
Chen JT; Tatsuki Y; Hirai Y; Hasumi K
Gan To Kagaku Ryoho; 1993 Feb; 20(2):265-70. PubMed ID: 8434965
[TBL] [Abstract][Full Text] [Related]
6. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C
Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
[No Abstract] [Full Text] [Related]
7. [Effectiveness of cisplatin alone and in combination within the scope of primary therapy of ovarian cancer. Results of a prospective multicenter study].
Richter P; Krafft W; Müller U; Brückmann D; Homann S; König EM; Lotze P; Morack G; Neubert S; Nöschel H
Zentralbl Gynakol; 1990; 112(7):421-9. PubMed ID: 1695049
[TBL] [Abstract][Full Text] [Related]
8. [Combined chemotherapy including platinum derivatives in the combined treatment of patients with stage-III to -IV ovarian cancer].
Perevodchikova NI; Gorbunova VA; Grigorova TM; Kozachenko VP; Marenich AF
Vestn Akad Med Nauk SSSR; 1986; (5):8-11. PubMed ID: 3755271
[No Abstract] [Full Text] [Related]
9. The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer.
Levin L; Hryniuk W
Semin Oncol; 1987 Dec; 14(4 Suppl 4):12-9. PubMed ID: 3120317
[TBL] [Abstract][Full Text] [Related]
10. Treatment of advanced epithelial ovarian cancer using cisplatin, adriamycin and cytoxan--the Indiana University experience.
Ehrlich CE; Einhorn L; Stehman FB; Blessing J
Clin Obstet Gynaecol; 1983 Aug; 10(2):325-35. PubMed ID: 6688562
[No Abstract] [Full Text] [Related]
11. [Phase III study of DWA2114R for ovarian cancer].
Kato T; Yakushiji M; Nishimura H; Terashima Y; Sasaki H; Yamabe T; Yajima A; Fujimoto S; Hashimoto M; Nishiya I
Gan To Kagaku Ryoho; 1992 Aug; 19(9):1285-93. PubMed ID: 1503482
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of advanced ovarian cancer with cis-dichlorodiammine platinum (CDDP) as single agent or cddp in combination with adriamycin (ADM)].
Nishimura H; Yamada T; Hagio Y; Inoue T; Tsunawaki A; Yakushiji M; Kato T
Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 1):938-43. PubMed ID: 6683483
[TBL] [Abstract][Full Text] [Related]
13. [Cisplatin, adriamycin and cyclophosphamide combination chemotherapy of epithelial ovarian cancer].
Sawada M; Ozaki M; Inagaki M; Hongo J; Hirota Y; Takayama K; Arimoto Y; Wada T; Taki I; Yanagita T
Gan To Kagaku Ryoho; 1987 Dec; 14(12):3301-4. PubMed ID: 3120644
[TBL] [Abstract][Full Text] [Related]
14. [Chemotherapy in clinical stage III cancer of the ovary. Use of 1 and 2 agents].
Torres Lobatón A; García Baños J; Nieto Riande P; Flores López G; Martínez Macías R
Ginecol Obstet Mex; 1986 Jan; 54():3-7. PubMed ID: 3699490
[No Abstract] [Full Text] [Related]
15. [Tumor chemotherapy of ovarian cancer patients in advanced age].
Behling H; Schirmer A; Krafft W; Brückmann D
Zentralbl Gynakol; 1988; 110(2):95-101. PubMed ID: 3364065
[TBL] [Abstract][Full Text] [Related]
16. Subrenal capsule assay as a predictor of clinical response of ovarian cancer to chemotherapy: Part II.
Mäenpää J
Obstet Gynecol; 1985 Nov; 66(5):714-8. PubMed ID: 3903584
[TBL] [Abstract][Full Text] [Related]
17. Re: Mucinous ovarian cancer.
Omura GA
Gynecol Oncol; 2005 Dec; 99(3):789; author reply 789-90. PubMed ID: 16125757
[No Abstract] [Full Text] [Related]
18. [Use of metoclopramide and dexamethasone in preventing vomiting associated with antineoplastic chemotherapy].
Sobkowski W; Jassem J
Pol Tyg Lek; 1987 Jul 6-7; 42(27-28):841-3. PubMed ID: 3684761
[No Abstract] [Full Text] [Related]
19. [Consensus and new development in epithelial ovarian cancer chemotherapy in 1995].
Hatae M; Onishi Y; Maeda Y; Nakamura T; Maeda T; Wada T
Gan To Kagaku Ryoho; 1995 Aug; 22(9):1182-9. PubMed ID: 7661570
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin, doxorubicin, and cyclophosphamide (PAC) in the treatment of mixed mesodermal tumor of the ovary.
Wheelock J; Hancock K; Smith K
Cancer Treat Rep; 1987 Dec; 71(12):1275-6. PubMed ID: 3690537
[No Abstract] [Full Text] [Related]
[Next] [New Search]